1. Medical history: There are no symptoms in the early stage. The early symptoms of some prostate cancer patients are usually not the symptoms of lower urinary tract obstruction, but the manifestations caused by local spread and bone metastasis. It is very important to know the patient’s family history of prostate cancer. For men with positive family history of prostate cancer, they should be examined and followed up regularly from the age of 40. 2. Rectal examination: meticulous rectal examination (DRE) helps to diagnose and stage prostate cancer. The typical rectal examination signs of prostate cancer are hard as a stone, poorly defined borders, irregular nodules, no pressure pain, and poor mobility, but the difference is large, and the infiltrated and highly malignant cancer foci may be quite soft. 3.Prostate specific antigen (PSA) test: Serum PSA is currently an important and reliable tumor marker for diagnosing prostate cancer, assessing the effect of various treatments and predicting prognosis. In healthy men, serum PSA value is generally 0-4ng/mL. Transrectal ultrasonography: There are three ways of prostate ultrasonography: transabdominal, transrectal and transurethral, among which transrectal ultrasonography is most commonly used. Transrectal ultrasound (TRUS) can clearly show the structure, migration zone and blood flow changes in the prostate, and accurately measure the volume of the prostate and the masses in the prostate. 5. Transrectal prostate puncture biopsy: Guided by transrectal ultrasonography (TRUS), not only is the definite or suspicious lesion punctured, but the prostate is also partitioned so that it can be punctured systematically to improve the detection rate. 6.CT/MRICT and MRI: Both have low diagnostic rates for cancer foci in the prostate, but can visualize pelvic lymph node metastasis, extra-prostatic envelope infiltration, and distant organ metastases, which can be helpful for clinical staging. 7.Radionuclide bone scan: Radionuclide bone scan is a non-invasive test that can detect bone metastases in prostate cancer patients. It can generally detect prostate cancer bone metastases 3-6 months or even longer than X-ray. Radioimmunoimaging: Radioimmunoimaging is a technique that uses anti-tumor antibody as the carrier and radionuclide as the “warhead” to image the primary and/or metastatic lesions of prostate cancer, which can be used for patients with advanced prostate cancer. It can be used for patients with advanced prostate cancer. It can also be used for concurrent treatment if a therapeutic radionuclide is carried.